
ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer
Camizestrant (AstraZeneca), used in combination with a CDK4/6 inhibitor, resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when used as a first-line treatment in patients with ESR1-mutated …